Patent · US Active

RNAi modulation of TGF-beta and therapeutic uses thereof

US7846908B2 · kind B2 · utility

0Cited by

10References

32Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Hans-Peter Vornlocher · Bayreuth, DE
Pamela Tan · Kulmbach, DE
Rainer Constien · Kulmbach, DE

Key dates

Filing date	Mar 15, 2007
Grant date	Dec 7, 2010
Priority date	—
Expiry date	Jul 17, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/321
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.